Financial Markets

Cancer immunotherapy and mRNA-based oncology platforms have not abolished mortality, but they have unsettled its predictability. Immune checkpoint inhibitors targeting...

Home-based medical care and concierge subscription models have moved from niche experimentation to durable growth vectors in U.S. healthcare. Demographic...

Healthcare affordability has reasserted itself as a dominant theme across employer forums, policy briefings, and financial disclosures over the past...

GLP-1 receptor agonists—marketed under brand names such as Ozempic and Wegovy—now reach an estimated one in eight American adults, according...

Continuous glucose monitors (CGMs), once reserved almost exclusively for patients with type 1 diabetes and select insulin-dependent populations, are now...

Over the past two weeks, healthcare financial discourse across earnings calls, investor notes, and sector research briefings has converged on...

Genetic testing has moved from clinical edge case to reimbursement flashpoint, and recent oversight reporting on Medicare Part B spending...

Search and social discourse over the past two weeks show sustained, high-volume engagement around healthcare costs, medical debt, insurance denials,...

The modern health‑insurance risk pool may be undone not by a pandemic or a demographic wave, but by a weekly...

Cognitive decline has quietly become one of the most expensive line items in modern healthcare, and the bill is only...

Clinical improvement and financial improvement are often assumed to move in the same direction. In healthcare payment systems, that alignment...

Transparency rules changed who asks the first question Procurement conversations historically opened with capability and differentiation. Increasingly they open with...